Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer
PLIN1, perilipin-1
A single molecular entity simultaneously activates both the GLP-1 receptor and the amylin receptor (calcitonin receptor complex), combining two complementary satiety and metabolic pathways: GLP-1 receptor activation : Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction through hypothalamic signaling Amylin receptor activation : Additional satiety signaling through the area postrema, complementary gastric emptying delay, and glucagon suppression through a distinct mechanism The unimolecular design means both receptor activations occur at a fixed ratio determined by the molecular structure
Each capsule contains 2MG GHK-Cu , 500MCG KPV , 500MCG TB-500 , and 500MCG BPC-157 Salt Arginate , designed for controlled laboratory investigations involving copper peptide signaling, extracellular matrix pathway research, peptide-fragment biology, tissue-response models, inflammation-response pathways, cellular repair-associated signaling, and peptide stability research
Estimates suggest oral bioavailability for peptides like BPC-157 may be only 1-2%, meaning massive doses would be required to achieve systemic effects
